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Cerebral toxoplasmosis is the most common neurologic opportunistic infection in HIV-infected patients. Excretory–secretory antigens
(ESA) are the majority of the circulating antigens in sera from hosts with acute toxoplasmosis, and their usefulness as antigens has been shown.
This study considered whether it could find anti-ESA antibodies in cerebrospinal fluid (CSF) and whether these antibodies can be markers of
active infection. Samples of CSF from 270 HIV-infected patients were analyzed and divided into 3 groups according to the presence or absence
of active toxoplasmosis. Group I: 99 patients with cerebral toxoplasmosis; group II: 112 patients with other opportunistic neurologic diseases
and seropositive for toxoplasmosis; and group III: 59 patients with other opportunistic neurologic diseases and seronegative for toxoplasmosis.
Toxoplasma gondii ESA and a crude tachyzoite antigen were used as antigens using ELISA and immunoblotting. The statistical analysis was
done using the F test and unpaired Student's t test. Crude tachyzoite antigen: mean ELISA-relative values ± standard error for CSF of groups I
and II were 7.0 ± 0.27 and 3.9 ± 0.19, respectively. Variance analysis revealed that results of both groups of patients were statistically different
(1.80, P = 0.0025). The difference between the mean results was 3.0 ± 0.3, and the Student's t test value was 9.41 (P = 0.0001). Samples from
groups I and II were reactive by immunoblotting, with similar intensities. In ESA-ELISA, themean for group I was 9.0 ± 0.39. Group II showed a
mean value of 2.7 ± 0.12. Both groups were statistically different (9.16, P b 0.001). However, in ESA, the difference between the mean results
was higher (6.2 ± 0.39) and the Student's t test value was 16.04 (P b 0.0001). Similar results were shown in immunoblotting where a CSF sample
from group I reacted well with ESA, and the sample from a group II patient failed to do so. The mean ELISA-relative value of the control group
(group III) was 0.5 ± 0.09 for the first antigen and 0.4 ± 0.22 for the second. ESA-ELISA and/or immunoblotting of CSF samples can be used for
diagnosis of cerebral toxoplasmosis in association with clinical, serologic, and radiological information, thus providing a simple straightforward
methodology, particularly suitable in countries with high prevalence of latent toxoplasmosis in the general population.
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Toxoplasmosis, caused by the protozoan Toxoplasma
gondii, is a common parasitic infection in humans, with a
worldwide distribution. The prevalence of T. gondii infection
varies among different geographical regions, and its acute
infection is characterized by nonspecific symptoms with
consequent formation of cysts that may remain in latent
form in many organs (Dubey, 1996; Dubey et al., 1998;
Hill et al., 2005). Reactivation of a latent infection occurs
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diseases, especially cerebral toxoplasmosis (Dubey, 1996;
Hill and Dubey, 2002; Pereira-Chioccola et al., 2009). The
prevalence rates of latent Toxoplasma infections in human
immunodeficiency virus (HIV)–infected patients have been
found to vary greatly from 3% to 97% (Ammassari et al.,
2000; Antinori et al., 2004; Nissapatorn, 2009; Sacktor,
2002). Prior to the highly active antiretroviral therapy
(HAART) era, cerebral toxoplasmosis was the most
common focal cerebral lesion detected in HIV-infected
patients with Toxoplasma infection, occurring in approxi-
mately half of Toxoplasma-seropositive patients (Beaman
et al., 1992; Luft and Remington, 1992; Oksenhendler et
al., 1994). Currently, this situation is still critical in
resource-limited settings, where HAART is not available.
In Brazil, despite universal and free access to HAART and
a decrease of cases, cerebral toxoplasmosis still accounts
for high morbidity and mortality (Vidal et al., 2005).
Although the definitive diagnosis of cerebral toxoplas-
mosis requires demonstration of tachyzoites in the brain by
biopsy or necropsy, in clinical practice, the treatment is
usually initiated upon a presumptive diagnosis, based on
clinical and radiological features. However, sometimes it
may be confused with other diseases (Alfonso et al., 2009).
The inclusion of polymerase chain reaction (PCR) is an
important tool in cerebral toxoplasmosis diagnosis (Bastien,
2002; Colombo et al., 2005; Mesquita et al., 2010a, 2010b;
Vidal et al., 2004), but it is still unavailable in most medical
centers, principally in developing countries. As a significant
portion of the world population is infected with T. gondii, the
serologic diagnosis is not so relevant in defining the cerebral
toxoplasmosis diagnosis, but some studies suggested that
high titers might be indicative of the active disease or higher
risk to develop it (Colombo et al., 2005; Derouin et al., 1996;
Hellerbrand et al., 1996). It is believed that approximately
50% of patients with focal encephalitis caused by T. gondii
have specific antibodies in cerebrospinal fluid (CSF)
(Wainstein et al., 1993) and most of them have a proportional
increase in intrathecal production of Toxoplasma antibodies
(Potasman et al., 1988). However, there are few reports about
this production; hence, further research on it is important as it
represents an alternative in the diagnosis of toxoplasmosis,
especially regarding the use of different antigens in the tests
for detection of such antibodies.
The active secretion of antigens by T. gondii may be an
essential part of the low-grade stimulation or boosting of the
immune system, as these antigens have been shown to
stimulate an antibody as well as a T-cell response
(Carruthers, 2002; Duquesne et al., 1990). A group of the
most important of these antigens has been documented for
parasite excretory–secretory antigens (ESA) that represent
the majority of the circulating antigens in sera from hosts
with acute toxoplasmosis (Cesbron-Delauw and Capron,
1993; Prigione et al., 2000; Tilley et al., 1997). ESA are
produced by tachyzoites, the form responsible for disse-
minating the infection, and play an important role instimulation of the humoral and cellular immune responses
to control infection (Costa-Silva et al., 2008; Ge et al., 2008).
The usefulness of ESA as an antigen in serologic diagnosis
has been shown recently (Mattos et al., 2011; Meira et al.,
2008). ESA was able to distinguish sera from patients with
cerebral or ocular toxoplasmosis from asymptomatic in-
dividuals. Normally, sera from patients with active disease
have a 3-fold higher titer than those from chronic individuals.
This study considers 2 questions. First, could anti-ESA
antibodies be found in the cerebrospinal fluid? Second,
can anti-ESA antibodies detected in CSF be markers of
active disease?2. Materials and methods
2.1. Patients and clinical samples
This study was conducted using CSF samples from HIV-
infected patients admitted at Emilio Ribas Institute of
Infectious Diseases, a tertiary teaching hospital in Sao Paulo,
Brazil. All patients were over 18 years of age and without
treatment with HAART until the sample collection. Samples
received by our laboratory suspected of cerebral toxoplasmosis
were tested during routine diagnosis. The tests included i)
indirect immunofluorescence test; ii) conventional enzyme-
linked immunosorbent assay (ELISA) (Colombo et al., 2005);
iii) conventional PCR (cPCR) using the primer pair B22/B23,
which amplified a 115-base pair sequence of the T. gondii B1
gene (Burg et al., 1989; Vidal et al., 2004); and iv) real-time
quantitative PCR (rPCR) using the B1Tg primer set which
amplified another region of the B1 gene. A TaqMan probe was
dye labeled with FAM and had NFQ as a reporter quencher
(Mesquita et al., 2010a). Around 3 mL of CSF was collected
from each patient, before or until the third day of the specific
therapy for toxoplasmosis. We selected 270 CSF samples of
HIV-infected patients according to their clinical and laboratory
diagnosis. Three groups were formed according to the
presence or absence of active toxoplasmosis. Group I was
composed of CSF from 99 patients (58% male and 42%
female) with cerebral toxoplasmosis. The case definition for
toxoplasmosis included the criteria of progressive neurologic
deficits; contrast-enhancing mass lesion(s) on computed
tomography; and successful response within 2 weeks to
specific treatment (Portegies et al., 2004; Vidal et al., 2005). In
addition, all patients had positive serology and at least 1
positive cPCR/rPCR for T. gondii. Group II was composed of
CSF from 112 patients (56% male and 44% female) with
other opportunistic neurologic diseases and seropositive for
toxoplasmosis. All patients had negative cPCR/rPCR for
T. gondii. Group III had CSF samples from 59 patients
(59% male and 41% female) with other opportunistic
neurologic diseases, seronegative for toxoplasmosis, and
negative cPCR/rPCR for T. gondii. In groups II and III,
patients had other diseases such as cytomegalovirus enceph-
alitis, cryptococcal meningoencephalitis, progressive multi-
focal leukoencephalopathy, HIV-associated cognitive motor
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disease. Due to the impossibility of obtaining CSF from
healthy individuals, a CSF panel of 20 patients with other
neurologic diseases (seronegative for toxoplasmosis) was used
to determine the cutoff for each reaction. These CSF samples
were not included in the groups. The ethics committees of the
participating institutions approved this study.
2.2. T. gondii and antigens
T. gondii maintenance and antigen preparation were done
as described before (Meira et al., 2008). Briefly, RH strain
tachyzoites were grown and maintained in Swiss mice ascites
by intraperitoneal inoculation. The parasite pellets were
washed twice, counted, and suspended in phosphate-buffered
saline (PBS, pH 7.2) at different concentrations for infecting
tissue cultures and preparing antigens for conventional
ELISA. Alternatively, tachyzoites were maintained in
VERO cells (ATCC CCL-81), at 37 °C 5% CO2, in fetal
bovine serum-free medium VPM SFM AGT (Gibco-Invitro-
gen, Life Technology - Invitrogen, Brasil) (Costa-Silva et al.,
2011). The tissue culture parasites were used for immuno-
blotting, and the cultured infected cell supernatants were used
in ESA recovery. For conventional ELISA, tachyzoites were
sonicated and disrupted by ultra-som (Sonic Dismembrator
Quigley, USA) for 10 cycles of 1.0 A/min, for 5 min with 2-
min intervals; the crude antigen was dissolved in 0.3 mol/L
NaCl; and the protein concentration was determined. For
immunoblotting, the crude tachyzoite antigen was composed
of 1 × 107 tissue culture tachyzoites solubilized in 50 μL of
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer, containing 2% SDS, 50 mmol/L
Tris-HCl, 5% 2-mercaptoethanol, 10% glycerol, and 0.01%
bromophenol blue, boiled and run in 10% polyacrylamide-
SDS gels. ESA were used as antigen source in immunoblot-
ting and ELISA (ESA-ELISA). The proteins were recovered
from infected culture supernatant that contained tachyzoites.
Before tachyzoite infection, VERO cells were previously
washed 3 times and the medium was replaced by another
aliquot. After 48 h postinfection, culture supernatants were
harvested, filtered through a 0.22-μmpore size filter, and a 10
μg/mL cocktail of protease inhibitors was added containing
(per milliliter) 20 μm AEBSF (4-(2-aminoethyl)benzenesul-
fonyl fluoride hydrochloride), 10 μmEDTA, 1.3 μmbestatin,
0.14 μm E-64, 10 nm leupeptin, and 3 nm aprotinin. The
supernatants, referred to as ESA, were concentrated in a
Speed Vac (Jouan S.A., evaporator centrifuge RC 10.09,
Saint-Herblain, Cedex, France) for 4 h and dialyzed against
PBS overnight at 4 °C. ESA concentrations were determined
by dilutions for use in ESA-ELISA and immunoblotting.
2.3. ELISA and immunoblotting
ESA and a crude tachyzoite antigen were used as
antigens to evaluate the CSF samples using ELISA and
immunoblotting. The methodologies were described before
for use in serum samples (Colombo et al., 2005; Meiraet al., 2008) and adapted for use in CSF. For immuno-
blotting, ESA and lysed tachyzoites (20 μL per line) were
boiled and fractionated by a run in SDS–10% PAGE. The
proteins were transferred to nitrocellulose membranes, cut
into 3–4-mm-wide strips, blocked for 1 h with 5% skim
milk-PBS, and incubated with CSF diluted 1:2 at room
temperature. After 1 h, the strips were washed with PBS
and incubated 1 h at room temperature with goat
horseradish peroxidase–conjugated anti-human IgG diluted
(1:500) in 5% skim milk-PBS. Bound antibodies were
visualized after incubation with 0.03% 4-chloro-1-naphthol
(Sigma-Aldrich) in methanol, 50 mmol/L Tris-HCl
(pH 7.6), and 0.1% H2O2. For ELISA, the reactions were
performed with microtiter polystyrene plates (flat bottom,
low binding, Corning, Corning Incorporated, USA). Each
well was incubated overnight at 4 °C with the antigen
(20 μg/mL of ESA and 1 μg/mL of crude tachyzoite
antigen) dissolved in 0.1 mL of 0.1 mol/L NaHCO3
(pH 8.5). After removal of the unbound antibodies by
washing the plates with PBS (pH 7.2) containing 0.05%
Tween 20, the free binding sites were blocked by treating
the wells with 5% skim milk-PBS. After 60 min, 50 μL of
each CSF sample diluted 1:2 in 5% skim milk-PBS was
incubated for 60 min at 37 °C. After 5 washes with PBS-
Tween 20, the wells were incubated for another 60 min at
37 °C with a horseradish peroxidase–conjugated goat anti-
human immunoglobulin G diluted 1:10,000 in 5% skim
milk-PBS. After a new wash cycle with PBS-Tween 20,
substrate solution (0.1 mol/L citric acid, 0.2 mol/L
Na2HPO4, 0.05% o-phenylenediamine, 0.1% H2O2) was
added to each well. The plates were left to stand at room
temperature in the dark for 30 min. Color development was
stopped by adding 50 μL of 4N H2SO4, and the absorbance
was measured with an ELISA reader (Labsystems Multis-
kan MS Plate Reader, Minneapolis, MN) with a 492-nm
filter. The CSF samples were assayed in duplicate. The
absorbance values were subtracted from the background,
and the arithmetic mean was calculated. The cutoff was
calculated in each reaction using a CSF panel of 20
patients seronegative for toxoplasmosis described above.
ELISA and immunoblotting standardizations were previ-
ously determined using a panel of 30 CSF samples (10 of
each group). Different concentrations of ESA (10 to 320
μg/mL) on the microtiter plates, different conjugate
dilutions (1:2,500 to 1:20,000), and different CSF dilutions
(1:1 to 1:128) were tested (data not shown).
2.4. Data analysis
The cutoff corresponded to the mean plus 2 times the
standard deviation of the optical density (OD, 492 nm) of the
20 negative CSF samples. The OD results were transformed
to ELISA-relative values and are shown in the figures. The
ELISA-relative values represent the ratio of the absorbance
of each CSF sample at an optical density of 492 nm (A492) to
the cutoff value (CSF OD/cutoff OD). Values greater than
1.0 were considered reactive.
282 C.S. Meira et al. / Diagnostic Microbiology and Infectious Disease 71 (2011) 279–285The results were statistically evaluated by the computer
program GraphPad Prism 5.0 (GraphPad Software, CA).
Differences between the mean ELISA-relative values in
groups I (active toxoplasmosis) and II (only seropositive) for
ESA and crude tachyzoite antigen were tested for signifi-
cance by using variance analyses, calculated by the F test.
The coefficient of similarity between both groups was
calculated by unpaired Student's t test (2-tailed). Differences
or similarities were considered statistically significant when
P value was less than 0.05.3. Results
The first step was to establish the conditions for ELISA
and immunoblotting for CSF samples. The checkerboard
assay performed with both antigens in ELISA determined the
optimal working dilutions of the crude tachyzoite antigen (1
μg/mL) and ESA (20 μg/mL) in alkaline buffer (0.1 mol/L
NaHCO3, pH 8.5), as well as the microtiter polystyrene plate
type (low binding). The optimal working dilution for CSF
samples was 1:2; and conjugate dilution was 1:10,000. The
intra- and interassay reproducibility were also checked.
These experimental conditions yielded the greatest differ-
ence in OD between positive and negative samples. ForEL
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Fig. 1. Immunologic reactivity of the crude tachyzoite lysate (A) and T. gondii exc
samples were from 99 patients with cerebral toxoplasmosis and AIDS (group I, ci
diseases and AIDS (group II, squares), and 59 patients seronegative for toxoplasmos
were calculated as the ratio of the absorbance of each CSF sample at an optical den
and Methods section). Values greater than 1.0 were considered reactive. The horizo
group II, 0.5 and 0.4 in group III. (C) and (D) show the immunoblotting analysis o
PAGE and transferred to a nitrocellulose. A CSF sample from each group (I, II, aimmunoblotting, the standardization assays were performed
with ESA. The optimal working dilution for solubilization
(20–30 μL) was 4:1 in the SDS-PAGE sample buffer. The
optimal working dilution for CSF samples was 1:2 and for
conjugate dilution was 1:500. The reactivity of the CSF for
both antigens was assayed in parallel in order to maintain the
same laboratorial conditions.
The CSF results, using the crude tachyzoite antigen, are
shown in Fig. 1A. The mean ELISA-relative values ±
standard error (SE) for CSF of group I (patients with cerebral
toxoplasmosis) and group II (patients with other opportu-
nistic diseases and seropositive for toxoplasmosis) were
7.0 ± 0.27 and 3.9 ± 0.19, respectively. Statistical analysis,
using the Student's t test and F test, was done to determine
whether the crude tachyzoite antigen was able to distinguish
CSF from patients with active infection (group I) from
chronic ones (group II). As shown in Table 1, variance
analysis by the F test revealed that results of both groups of
patients were statistically different (1.80, P = 0.0025). The
difference between the mean results was 3.0 ± 0.3 and the
Student's t test value was 9.41 (P = 0.0001). The values for
the CSF samples from group III (patients with other
neurologic diseases and negative for toxoplasmosis) were
0.5 ± 0.09. As expected, CSF samples collected from both
groups (I and II) of patients were reactive (strips I and II)  Groups
B
n = 112n = 99 n = 59
D
        2       I       II  III
 -
 -
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.8 -
reted–secreted antigens (ESA) (B) against CSF samples in ELISA. The CSF
rcles), 112 patients seropositive for toxoplasmosis but with other neurologic
is, with other neurologic diseases and AIDS (group III, triangles). The results
sity of 492 nm (A492) to the cutoff value (described in details in the Material
ntal lines represent the arithmetic means: 7.0 and 9.0 in group I, 3.9 and 2.7 in
f a lysate (1 × 107 tachyzoites) (C1) and ESA (D2), separated by 10% SDS-
nd III) was incubated with nitrocellulose strips.
Table 1
ESA-ELISA and conventional ELISA (crude tachyzoite antigen) results:
statistical analysis of differences between groups I (active toxoplasmosis)
and group II (only seropositive) patients
Statistical test Crude tachyzoite antigen ESA
Group I (n = 99) 7.0 ± 0.27a 9.0 ± 0.39a
Group II (n = 112) 3.9 ± 0.19a 2.7 ± 0.12a
Unpaired t test (2-tailed) 9.41 16.04
P value 0.0001 b0.0001
Difference between means 3.0 ± 0.32a 6.2 ± 0.39a
95% Confidence interval 2.4 to 3.7 5.5 to 7.0
R2 0.30 0.55
F test (to compare variances) 1.80b 9.16b
P value 0.0025 b0.0001
a Values expressed as mean ± SE.
b The variances are significantly different in both groups.
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ting, with similar intensities (Fig. 1C).
In parallel, the same samples in ESA-ELISA were tested
(Fig. 1B). The mean ELISA-relative values ± SE for the CSF
samples of group I was 9.0 ± 0.39. In contrast, the CSF
samples of group II showed a mean value of 2.7 ± 0.12. As
for the other antigen, the variance analysis also showed that
results of both groups of patients were statistically different
(9.16, P b 0.0001). However, in ESA, the difference
between the mean results was higher (6.2 ± 0.39) and the
Student's t test value was 16.04 (P b 0.0001). These results
were further confirmed by immunoblotting, as shown in
Fig. 1D. A CSF sample from group I (strip I) reacted well
with ESA (strip II). The CSF sample collected from a group
II patient (strip II) failed to do so. The mean ELISA-relative
value of the control group (group III) was 0.4 ± 0.22.
Next, the distribution of ELISA relative values obtained
after testing the reactivity using the crude tachyzoite lysate
and ESA was analyzed by linear regression. As shown in0 5 10 15 20 25
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Fig. 2. Correlation index (R2) between the ELISA results using 2 antigens,
the crude tachyzoite lysate (x axis), and ESA (y axis). Each point represents
the reactivity of each CSF sample of group II patients (with other
opportunistic diseases and seropositive for toxoplasmosis) (A) and group I
patients (with cerebral toxoplasmosis) (B). Each result was calculated as the
ratio of the absorbance of each sample at 492 nm (A492) to the cutoff value.
Values greater than 1.0 were considered reactive.Fig. 2A, CSF samples from group II reacted almost equally
against the crude tachyzoite lysate and ESA. The correlation
index (R2) was 0.30 (Table 1). In parallel, CSF samples from
patients with cerebral toxoplasmosis had high reactivity with
ESA compared with those with crude tachyzoite lysate as
shown in Fig. 2B. The correlation index was 0.55 (Table 1).
4. Discussion
Most of the expansive lesions of the central nervous
system detected in HIV-infected patients are attributed to
reactivation of latent T. gondii infection caused by severe
immunosuppression. The definitive diagnosis of such lesions
requires sophisticated techniques or invasive procedures that
are not free of risk. In recent years, laboratory methods such
as immunologic and molecular ones have contributed to
establishing cerebral toxoplasmosis diagnosis (Collazos,
2003; Pereira-Chioccola et al., 2009).
Different immunologic methods for detecting circulating
T. gondii antigens or specific antibodies have been tested
in an attempt to establish the diagnosis of cerebral
toxoplasmosis in HIV-infected patients (Dannemann et al.,
1992; Darcy et al., 1991; Fachado et al., 1994; Luft et al., 1993).
These studies showed that more than 50% of patients with
cerebral toxoplasmosis present specific antibodies in the CSF,
since the rupture of the blood–CSF barrier due to any type of
etiology may be accompanied by passive passage of antibodies
from serum to CSF. Another factor to be considered is that
toxoplasmosis is a predominantly parenchymatous disease and
that the presence or absence of local antibody production
detected by CSF examination may depend on the proximity of
the lesion to the meninges (Borges and Figueiredo, 2004; Luft
et al., 1993; Patel et al., 1993; Tuazon 1989).
The capacity of ESA as a serologic marker for the
diagnosis of cerebral toxoplasmosis in HIV-infected patients
has been demonstrated, since they are produced by
tachyzoites, the form responsible for disseminating the
infection. In addition, ESA play an important role in
stimulating humoral and cellular immune responses to
control infection (Cérède et al., 2005; Costa-Silva et al.,
2008; Meira et al., 2008). Patients with cerebral toxoplas-
mosis have high anti-T. gondii IgG titers with high avidity
(Colombo et al., 2005; Mechain et al., 2000). In this phase,
tachyzoites are released from the quiescent cysts and a
considerable proportion of excreted/secreted antigens are
released, eliciting the specific immune response to ESA
(Pereira-Chioccola et al., 2009). When ESA were used as
antigen (in ELISA or immunoblotting), CSF samples from
patients with the active disease had a 3-fold higher titer than
those from other neurologic diseases.
Infected individuals with latent infection by toxoplasmosis
remain asymptomatic. Despite the presence of the T. gondii
antibodies, they have no or a low number of circulating
tachyzoites. In general, these antibodies are determined in
conventional serology, using as antigen the total extract of
tachyzoites, which consists of cytoplasmic and membrane
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sis and those from other neurologic diseases differed
slightly in reactivity when the crude tachyzoite antigen was
used in ELISA. However, in immunoblotting the reactivity
was similar.
All these data together confirm previous data (Meira et al.,
2008), which almost showed in serum samples that the crude
tachyzoite antigen, widely used in conventional diagnosis,
failed to distinguish both groups of patients. On the other
hand, ESA were able to distinguish the active from the
asymptomatic infection both in sera and in CSF samples.
Various studies have reported on the value of the
immunologic diagnosis in CSF with limited sensitivity and
specificity (around 60% to70%) (Collazos, 2003), since
antibodies may not be detected in up to 5% of patients owing
to immune suppression (Contini, 2008; Luft and Chua, 2000;
Luft and Remington, 1992; Luft et al., 1984). However, this
study showed that anti-ESA antibodies are also present in
CSF from HIV-related cerebral toxoplasmosis patients.
Finally, for a proportion of HIV-infected patients with
cerebral toxoplasmosis, it is contraindicated to perform a
lumbar puncture due to the mass effect of 1 or more
expansive brain lesions. In these patients, both molecular and
immunologic tools could not to be used in CSF samples,
reflecting the difficulty of obtaining a less invasive and early
diagnosis and the need for continuous efforts to evaluate
alternative methodologies for managing HIV-related cere-
bral toxoplasmosis.
ESA-ELISA and/or immunoblotting done on CSF
samples can be used for diagnosis of cerebral toxoplasmosis
in association with clinical, serologic, and radiological
information, providing a simple straightforward methodol-
ogy, particularly suitable in countries with high prevalence
of latent toxoplasmosis in the general population.References
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